p38 and cancer: Yang gets yin

Cancer Biology and Therapy

Volumn 7, Issue 8, 2008, Pages 1241-1242

  Rovida, Elisabetta ^a   Dello Sbarba, Persio ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Dipartimento di Patologia e Oncologia Sperimentali   (Italy)

Author keywords

Cancer stem cells; Kinase inhibitors; MAPK; Molecularly tailored therapy; Oncosuppressor; p38; Personalized therapy

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN P53; RAF PROTEIN; RAS PROTEIN;

ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; DNA DAMAGE; HUMAN; NOTE; PROTEIN EXPRESSION;

EID: 49749120008     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.8.6636     Document Type: Note

References (20)

1. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999; 19:2435-44.
2. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26:3100-12.
3. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80:179-85.
4. Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 1996; 16:4504-11.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
6. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26:3279-90.
7. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2:717-26.
8. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995; 364:229-33.
9. Kummer JL, Rao PK, Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1997; 272:20490-4.
10. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81:807-69.
11. Kennedy NJ, Cellurale C, Davis RJ. A radical role for p38MAPK in tumor initiation. Cancer Cell 2007; 11:101-3.
12. Bulavin DV, Fornace AJ Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004; 92:95-118.
13. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007; 11:191-205.
14. Lavoie JN, L'Allemain G, Brunet A, Müller R, Pouysségur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271:20608-16.
15. 2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005; 17:37-48.
16. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ Jr, Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31:210-5.
17. Han J, Sun P. The pathways to tumor suppression via route p38.Trends Biochem Sci 2007; 32:364-71.
18. Faust D, Dolado I, Cuadrado A, Oesch F, Weiss C, Nebreda AR, Dietrich C. p38alpha MAPK is required for contact inhibition. Oncogene 2005; 24:7941-5.
19. Vaidya AA, Sharma MB, Kale VP. Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by inducing proliferative responses in them. Cancer Biol Ther 2008; This issue.
20. Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba P. The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells. Br J Haematol 2006; 135:653-9.